[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periampullary-carcinoma-resectable\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periampullary-carcinoma-resectable":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100645373","the-effect-of-braun-anastomosis-on-delayed-gastric-emptying-dge-in-reconstruction-after-pancreaticoduodenectomy-100645373",false,"NCT07681128","The Effect of Braun Anastomosis on Delayed Gastric Emptying (DGE) in Reconstruction After Pancreaticoduodenectomy","The Effect of Braun Anastomosis on Delayed Gastric Emptying (DGE) in Reconstruction After Pancreaticoduodenectomy: A Prospective Single-center Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years, male or female;\n* Scheduled to undergo curative pancreaticoduodenectomy (PD);\n* Undergoing PD for malignant or borderline tumors, with planned antecolic Billroth II reconstruction;\n* Mentally competent and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years;\n* Prior diagnosis of gastroparesis;\n* Benign disease as the indication for PD;\n* Previous history of upper gastrointestinal surgery;\n* Preoperative pyloric obstruction;\n* Planned pylorus-preserving pancreaticoduodenectomy (PPPD);\n* Patients who have received neoadjuvant or conversion therapy;\n* Preoperative glycated hemoglobin (HbA1c) \\> 7.5%;\n* Preoperative total bilirubin level \\> 200 μmol\u002FL;\n* Unable or unwilling to provide written informed consent.","ALL","18 Years",{"count":19,"type":20},264,"ESTIMATED","INTERVENTIONAL",[23],"NA","Pancreaticoduodenectomy (PD) is the only curative procedure for periampullary malignant tumors. Although modern perioperative management has greatly reduced postoperative mortality, delayed gastric emptying (DGE) remains one of the most common and troublesome complications after PD, with an incidence up to 30%. DGE leads to abdominal distension, nausea, vomiting, intolerance of oral diet, prolonged hospital stay, increased medical costs, delayed adjuvant therapy initiation, and impaired long-term nutritional recovery and quality of life.\n\nBraun anastomosis (BE) can reconstruct the gastrointestinal tract by side-to-side jejunojejunostomy between the afferent and efferent limbs, which may reduce intestinal stasis, bile reflux and afferent limb obstruction, and theoretically lower the risk of postoperative DGE. However, current clinical studies and meta-analyses remain controversial regarding the actual efficacy of BE in preventing DGE after PD. Some studies support that BE can reduce DGE incidence, shorten hospitalization and improve postoperative recovery, while others demonstrate no statistically significant benefit, or even concern about prolonged operative time and technical difficulty. Existing evidence is limited by small sample size, retrospective design and potential selection bias, and high-quality prospective randomized controlled trials are still lacking to confirm the clinical value of BE.\n\nThis study is designed as a prospective, single-center, randomized controlled trial, aiming to evaluate the impact of routine Braun anastomosis during digestive tract reconstruction on the incidence and severity of postoperative DGE in patients undergoing pancreaticoduodenectomy for malignant tumors. The results will provide high-level clinical evidence for the rational application of Braun anastomosis in PD reconstruction and guide standardized clinical practice.",[26],"Periampullary Carcinoma Resectable",[28,29,30],"Pancreaticoduodenectomy","Braun Anastomosis","Delayed Gastric Emptying","RECRUITING","2026-06-26",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2026-03-30",{"date":39,"type":20},"2028-09-30",{"name":41,"class":42},"Tianjin Medical University Cancer Institute and Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100599197","phase-3-neoadjuvant-vs-upfront-surgery-for-resectable-pancreatic-cancer-and-periampullary-cancer-100599197","NCT07081360","Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer","Neoadjuvant Chemotherapy Followed by Surgery Versus Upfront Surgery for Clearly Resectable Pancreatic Head Cancer and Periampullary Cancer: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Histologically or cytologically confirmed pancreatic head cancer or periampullary carcinoma(endoscopic ultrasound (EUS)-guided biopsy).\n* Clearly resectable disease as defined by National Comprehensive Cancer Network (NCCN) criteria on cross-sectional imaging:\n\nNo involvement or abutment of the celiac artery, common hepatic artery, superior mesenteric artery, or replaced right hepatic artery .\n\nLess than 180 degree interface between tumor and vessel wall of the portal vein or superior mesenteric vein, and patent portal vein\u002Fsplenic vein confluence No evidence of metastatic disease.\n\n* Eastern Cooperative Oncology Group (ECOG)=0-1 \\& American Society of Anesthesiologists (ASA) score \\\u003C4.\n* Written informed consent.\n* Medical history without previous pancreatic resection or pancreatic cancer.\n* Adequate organ function (liver, kidney, bone marrow) (serum creatinine ≤2.0 mg\u002FdL,reference range 0.5-1.20 mg\u002FdL; serum albumin ≥2.5 g\u002FdL, reference range 3.5-5.3; aspartate aminotransferase (AST) ≤95 U\u002FL, reference range 0-38; Alanine aminotransferase (ALT) ≤102 U\u002FL, reference range 0-41; prothrombin time ≤1.8, reference range 0-1.20; partial thromboplastin time ≤1.8, reference range 0.82-1.25; leukocyte count greater than 3.5×109\u002FL, reference range 4.2-9.0; platelet count greater than 100×109\u002FL, reference range 130-400; hemoglobin ≥9 g\u002FdL, reference range 12-16).\n\nExclusion Criteria:\n\n* Borderline resectable or locally advanced pancreatic or periampullary cancer.\n* Tumor at the body or tail of the pancreas.\n* Distant metastases.\n* Prior chemotherapy , surgery or radiotherapy for pancreatic cancer.\n* Severe comorbidities precluding surgery or chemotherapy.\n* Pregnancy or lactation.\n* Other neoplastic diseases (malignant)diagnosed in the past 5 years.\n* Major surgery or traumatic event in the past 28 days.","75 Years",{"count":53,"type":20},262,[55],"PHASE3","Adjuvant chemotherapy after surgery significantly improved the survival of pancreatic cancer (PC) patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy. Neoadjuvant chemotherapy might control potential metastatic lesions which are not being detected in early disease status and improve the R0 resection rate. In addition, it prevents futile surgery by selecting patients with rapid progression of disease. Furthermore, compared to chemotherapy administered after surgery, more patients can complete the planned chemotherapy schedule in neoadjuvant setting.\n\nThere are still few studies worldwide that prospectively explored the efficacy of neoadjuvant chemotherapy in resectable PC and periampullary cancer and the administration of neoadjuvant therapy in resectable PC depends on individual clinical judgment. Therefore, systematic and prospective clinical trials are essential to standardize treatment protocol in resectable PC and periampullary Cancer.\n\nThis randomized controlled trial compares neoadjuvant chemotherapy followed by surgery versus upfront surgery for patients with clearly resectable pancreatic head cancer and periampullary cancer. The study aims to determine if neoadjuvant chemotherapy improves overall survival compared to immediate surgery followed by adjuvant chemotherapy.",[58,59,26,60,61,62],"Pancreas Cancer","Periampullary Cancer","Pancreatic Cancer Resectable","Ampullary Cancer","Pancreas Adenocarcinoma",[64,65,28],"Pancreatic cancer","Neoadjuvant chemotherapy","2025-08-24",{"date":68,"type":35},"2025-08-29",{"date":70,"type":35},"2025-07-20",{"date":72,"type":20},"2028-08-20",{"name":74,"class":42},"Minia University"]